Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...

Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...

Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Adaptimmune Therapeutics announces 33% workforce reduction and restructuring to save $300 million through 2028. Company halts ...

Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...

ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, ...

Eli Lil­ly is now the sec­ond drug­mak­er to pro­pose a re­bate mod­el for 340B drug price dis­counts — and the sec­ond to ...

The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...

Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was ...

New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.